Aldeyra Therapeutics, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (23)

Latest Posts

About This Stock More About This Stock
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Article By: Benzinga
Saturday, April 27, 2019 6:05 PM EDT
Biotech stocks staged a recovery this week after being in the red in the previous two weeks.
In this article: BTX, BOLD, REGN, BIIB, GWPH, ALDX, HRTX, IONS, ADAP, NBRV, BHVN, NVS, SNY, RHHBY, ABBV
Read
RegeneRx Versus Restasis: Who Hits The $2 Billion Dry-Eye Jackpot?
Article By: Shock Exchange
Wednesday, October 4, 2017 6:29 PM EDT
A manhunt is on for the next dry-eye disruptor. RGRX and ALDX are two candidates. RGRX just completed Phase 3 testing. Its drug has shown success in head-to-head comparisons with Restasis and Xiidra. Will RGRX hit the dry-eye jackpot?
In this article: RGRX, ALDX, AGN Also: SHPG
Read
Aldeyra Raises Additional Capital To Fund Dry Eye Treatment
Article By: Shock Exchange
Wednesday, September 27, 2017 11:55 AM EDT
ALDX recently raised nearly $27MM to fund its dry eye treatment. Fresh capital gives ALDX flexibility to partner with big pharma for drug development or go it alone. The dry eye market offers huge upside for a new entrant. ALDX is a buy.
In this article: ALDX Also: AGN, SHPG, GILD, MRK
Read
Best Stock Charts - Wednesday, April 5
Article By: Robert Desmond
Wednesday, April 5, 2017 11:29 PM EDT
Overall our opinion on the market is that they are weak and getting weaker. We are focusing in on shorting the markets to make big profits to short side.
In this article: ECYT, QQQ, BBBY, CBOE, FIZZ, SCHN, COOL, RCON, GDX, GLD, IWM, NUGT, TZA, UUP, ALDX, AAOI
Read
Depomed To Acquire U.S. Rights To NUCYNTA®, NUCYNTA® ER; Amgen Presents First-Line Use Of Vectibix®
Article By: BioMedReports
Friday, January 16, 2015 3:44 AM EDT
Depomed Inc. announced it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion.
In this article: DEPO, AMGN, DDD, ADXS, ALDX, AMBS, AMED, BSDM, BMRN, CBMG, DVCR, GALE, GB, HTBX, HEB, ISRG, OMED, PMCB, PRGB, RGDX, TGTX, WCUI
Read

PARTNER HEADLINES

Latest Tweets for $ALDX

No tweets yet!